$AQST
Aquestive Therapeutics, Inc. Stock $aqst

$aqst Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000162828022005393 Filed on March 08, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$11.08M	$50.83M	$7.149M
YoY Change	54.96%	10.87%	-56.46%
Cost Of Revenue	$3.366M	$14.99M	$2.788M
YoY Change	20.73%	15.62%	-58.95%
Gross Profit	$7.712M	$35.84M	$4.361M
YoY Change	76.84%	8.99%	-54.7%
Gross Profit Margin	69.62%	70.51%	61.0%
Selling, General & Admin	$14.98M	$53.48M	$15.58M
YoY Change	-3.84%	-4.32%	-5.4%
% of Gross Profit	194.26%	149.19%	357.26%
Research & Development	$4.400M	$17.05M	$4.430M
YoY Change	-0.68%	-14.28%	44.77%
% of Gross Profit	57.05%	47.56%	101.58%
Depreciation & Amortization	$731.0K	$2.912M	$1.100M
YoY Change	-33.55%	-14.15%	42.86%
% of Gross Profit	9.48%	8.12%	25.22%
Operating Expenses	$19.38M	$85.51M	$20.01M
YoY Change	-3.14%	-3.64%	-23.98%
Operating Profit	-$11.67M	-$34.68M	-$15.65M
YoY Change	-25.43%	-19.15%	-6.27%
Interest Expense	-$3.454M	$10.05M	-$4.720M
YoY Change	-26.82%	-9.17%	72.89%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$28.95M	-$70.54M	-$20.37M
YoY Change	42.1%	26.45%	61.16%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$28.95M	-$70.54M	-$20.37M
YoY Change	42.11%	26.45%	61.19%
Net Earnings / Revenue	-261.28%	-138.77%	-284.91%
Basic Earnings Per Share		-$1.85
Diluted Earnings Per Share	-$716.2K	-$1.85	-$602.1K
COMMON SHARES
Basic Shares Outstanding	40.16M shares	38.08M shares	33.62M
Diluted Shares Outstanding		38.08M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.02M	$28.02M	$31.81M
YoY Change	-11.9%	-11.9%	-35.52%
Cash & Equivalents	$28.02M	$28.02M	$31.81M
Short-Term Investments
Other Short-Term Assets	$3.077M	$3.077M	$3.400M
YoY Change	-9.5%	-9.5%	13.33%
Inventory	$4.038M	$4.038M	$2.461M
Prepaid Expenses
Receivables	$12.12M	$12.12M	$6.960M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$47.26M	$47.26M	$44.63M
YoY Change	5.9%	5.89%	-34.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.055M	$7.780M	$6.873M
YoY Change	-26.45%	-24.61%	-29.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.903M	$903.0K	$7.836M
YoY Change	-11.91%	7.5%	2639.86%
Total Long-Term Assets	$14.73M	$14.73M	$18.26M
YoY Change	-19.31%	-19.27%	79.63%
TOTAL ASSETS
Total Short-Term Assets	$47.26M	$47.26M	$44.63M
Total Long-Term Assets	$14.73M	$14.73M	$18.26M
Total Assets	$61.99M	$61.99M	$62.88M
YoY Change	-1.42%	-1.41%	-19.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.314M	$8.314M	$7.089M
YoY Change	17.28%	17.26%	-42.24%
Accrued Expenses	$8.736M	$9.635M	$8.569M
YoY Change	1.95%	3.6%	56.51%
Deferred Revenue	$765.0K		$693.0K
YoY Change	10.39%		-14.02%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.025M	$2.025M	$2.580M
YoY Change	-21.51%	-21.51%
Total Short-Term Liabilities	$21.96M	$21.96M	$21.10M
YoY Change	4.08%	4.09%	13.74%
LONG-TERM LIABILITIES
Long-Term Debt	$51.55M	$51.55M	$34.33M
YoY Change	50.16%	50.16%	-43.11%
Other Long-Term Liabilities	$2.485M	$70.61M	$1.945M
YoY Change	27.76%	26.21%	43.01%
Total Long-Term Liabilities	$2.485M	$122.2M	$1.945M
YoY Change	27.76%	35.32%	43.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.96M	$21.96M	$21.10M
Total Long-Term Liabilities	$2.485M	$122.2M	$1.945M
Total Liabilities	$144.1M	$144.1M	$111.4M
YoY Change	29.4%	29.4%	31.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$256.8M		-$186.3M
YoY Change	37.87%		42.75%
Common Stock	$41.00K		$35.00K
YoY Change	17.14%		2.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$82.13M	-$82.13M	-$48.50M
YoY Change
Total Liabilities & Shareholders Equity	$61.99M	$61.99M	$62.88M
YoY Change	-1.42%	-1.41%	-19.87%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$28.95M	-$70.54M	-$20.37M
YoY Change	42.11%	26.45%	61.19%
Depreciation, Depletion And Amortization	$731.0K	$2.912M	$1.100M
YoY Change	-33.55%	-14.15%	42.86%
Cash From Operating Activities	-$8.061M	-$32.98M	-$13.51M
YoY Change	-40.33%	-27.45%	27.81%
INVESTING ACTIVITIES
Capital Expenditures	-$533.0K	$913.0K	-$240.0K
YoY Change	122.08%	76.6%	200.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$533.0K	-$913.0K	-$240.0K
YoY Change	122.08%	76.6%	200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.454M	$30.11M	28.49M
YoY Change	-80.86%	5.81%	-27.08%
NET CHANGE
Cash From Operating Activities	-8.061M	-$32.98M	-13.51M
Cash From Investing Activities	-533.0K	-$913.0K	-240.0K
Cash From Financing Activities	5.454M	$30.11M	28.49M
Net Change In Cash	-3.140M	-$3.783M	14.74M
YoY Change	-121.3%	-78.41%	-48.14%
FREE CASH FLOW
Cash From Operating Activities	-$8.061M	-$32.98M	-$13.51M
Capital Expenditures	-$533.0K	$913.0K	-$240.0K
Free Cash Flow	-$7.528M	-$33.89M	-$13.27M
YoY Change	-43.27%	-26.28%	26.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001398733
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-38599
CY2021	dei	Entity Registrant Name EntityRegistrantName	Aquestive Therapeutics, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3827296
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	30 Technology Drive
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Warren
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07059
CY2021	dei	City Area Code CityAreaCode	908
CY2021	dei	Local Phone Number LocalPhoneNumber	941-1900
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2021	dei	Trading Symbol TradingSymbol	AQST
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	110700000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41467608	shares
CY2021	dei	Auditor Firm AuditorFirmId	185
CY2021	dei	Auditor Name AuditorName	KPMG LLP
CY2021	dei	Auditor Location AuditorLocation	New York, New York
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28024000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31807000	USD
CY2021Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	12120000	USD
CY2020Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	6955000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	4038000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	2461000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3077000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3402000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	47259000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	44625000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5055000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6873000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2725000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3448000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	51000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	102000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6903000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7836000	USD
CY2021Q4	us-gaap	Assets Assets	61993000	USD
CY2020Q4	us-gaap	Assets Assets	62884000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8314000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7089000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8736000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8569000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	899000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	728000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	765000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	693000	USD
CY2021Q4	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Current TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedCurrent	1225000	USD
CY2020Q4	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Current TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedCurrent	1450000	USD
CY2021Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2025000	USD
CY2020Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2575000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21964000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21104000	USD
CY2021Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	51551000	USD
CY2020Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	34329000	USD
CY2021Q4	aqst	Liabilities Sale Of Future Revenue Net LiabilitiesSaleOfFutureRevenueNet	59059000	USD
CY2020Q4	aqst	Liabilities Sale Of Future Revenue Net LiabilitiesSaleOfFutureRevenueNet	47524000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1946000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2846000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	7122000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3633000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2485000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1945000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	144127000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	111381000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41228736	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41228736	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34569254	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34569254	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	41000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	35000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	174621000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	137725000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-256796000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-186257000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-82134000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-48497000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61993000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	62884000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50832000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45849000	USD
CY2021	aqst	Manufacture And Supply Costs ManufactureAndSupplyCosts	14989000	USD
CY2020	aqst	Manufacture And Supply Costs ManufactureAndSupplyCosts	12964000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17047000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19886000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	53475000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	55892000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	85511000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	88742000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-34679000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-42893000	USD
CY2021	us-gaap	Interest Expense InterestExpense	10049000	USD
CY2020	us-gaap	Interest Expense InterestExpense	11064000	USD
CY2021	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	12412000	USD
CY2020	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	1958000	USD
CY2021	us-gaap	Interest And Other Income InterestAndOtherIncome	423000	USD
CY2020	us-gaap	Interest And Other Income InterestAndOtherIncome	132000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13822000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-70539000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-55783000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-70539000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-55783000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-70539000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55783000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.85
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.85
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.66
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.66
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38077660	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38077660	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33651127	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33651127	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-6122000	USD
CY2020	aqst	Adjustments To Additional Paid In Capital Fair Value Of Warrants Issued AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrantsIssued	735000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6528000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-473000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-55783000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	158000	USD
CY2020	aqst	Apic Share Based Payment Arrangement Exercise Of Stock Options APICShareBasedPaymentArrangementExerciseOfStockOptions	2000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-99000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6557000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-48497000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	31069000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-1291000	USD
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	158000	USD
CY2021	aqst	Apic Share Based Payment Arrangement Exercise Of Stock Options APICShareBasedPaymentArrangementExerciseOfStockOptions	185000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-14000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6795000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-70539000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-82134000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-70539000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-55783000	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	299000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-188000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1258000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2964000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3443000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	6819000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	6581000	USD
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3731000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2587000	USD
CY2021	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	12253000	USD
CY2020	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	1938000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13822000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	5353000	USD
CY2020	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-6175000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1577000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-398000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	0	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7953000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1225000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5185000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-844000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2980000	USD
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3561000	USD
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-828000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32979000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45459000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	913000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	517000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-913000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-517000	USD
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	29780000	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	6215000	USD
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	158000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28457000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	185000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021	aqst	Proceeds From Sale Of Future Revenues Net ProceedsFromSaleOfFutureRevenuesNet	0	USD
CY2020	aqst	Proceeds From Sale Of Future Revenues Net ProceedsFromSaleOfFutureRevenuesNet	50000000	USD
CY2021	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	USD
CY2020	us-gaap	Repayments Of Debt RepaymentsOfDebt	22500000	USD
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2020	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2909000	USD
CY2021	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	USD
CY2020	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	2250000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	14000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	99000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30109000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3783000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17519000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	6438000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31807000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49326000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28024000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31807000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	8491000	USD
CY2021	us-gaap	Notes Issued1 NotesIssued1	0	USD
CY2020	us-gaap	Notes Issued1 NotesIssued1	4000000	USD
CY2021	aqst	Number Of Products Approved By Food And Drug Administration NumberOfProductsApprovedByFoodAndDrugAdministration	5	product
CY2021	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation and Principles of Consolidation<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the Securities and Exchange Commission, or SEC. The accounts of wholly owned subsidiaries are included in the consolidated financial statements. Other than corporate formation activities, no such subsidiaries have conducted any commercial, developmental or operational activities and none have customers or vendors. Certain reclassifications were made to conform to the current presentation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).</span></div>
CY2021	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and contingent liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates and assumptions often involve assessments of matters that are inherently uncertain and accordingly actual results could differ from those estimates. Significant items subject to estimates and assumptions include those related to revenue recognition, inventory costs, allowances for rebates from proprietary product sales, allowances for sales returns, the useful lives of fixed assets, the valuations of warrants issued and of share-based compensation, and contingencies.
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents are maintained are held by federally insured financial institutions that management believes are of high credit quality. The Company has not experienced any losses in such accounts and such amounts may exceed federally-insured limits. </span></div>Indivior, Sunovion, and three of the largest regional wholesalers represent our most significant customers and details on these relationships are outlined in Note 5.
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2021	aqst	Research And Development Project Duration ResearchAndDevelopmentProjectDuration	P3Y
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28024000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-256796000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45849000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50832000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50832000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45849000	USD
CY2021Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	9678000	USD
CY2020Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	4330000	USD
CY2021Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3087000	USD
CY2020Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3081000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	605000	USD
CY2020Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	416000	USD
CY2021Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	12120000	USD
CY2020Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	6955000	USD
CY2021Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3087000	USD
CY2020Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3081000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	124000	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	198000	USD
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
CY2020	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	282000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2020Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	416000	USD
CY2019Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	203000	USD
CY2021	aqst	Accounts Receivable Allowances Provision Related To Sales AccountsReceivableAllowancesProvisionRelatedToSales	1209000	USD
CY2020	aqst	Accounts Receivable Allowances Provision Related To Sales AccountsReceivableAllowancesProvisionRelatedToSales	731000	USD
CY2021	aqst	Accounts Receivable Allowances Credits And Payments AccountsReceivableAllowancesCreditsAndPayments	1020000	USD
CY2020	aqst	Accounts Receivable Allowances Credits And Payments AccountsReceivableAllowancesCreditsAndPayments	518000	USD
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	605000	USD
CY2020Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	416000	USD
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1442000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	789000	USD
CY2021Q4	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	1414000	USD
CY2020Q4	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	1128000	USD
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1182000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	544000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	4038000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	2461000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	44915000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47751000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39860000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	40878000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5055000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6873000	USD
CY2021	us-gaap	Depreciation Depreciation	2912000	USD
CY2020	us-gaap	Depreciation Depreciation	3392000	USD
CY2021	aqst	Number Of Leases NumberOfLeases	3	lease
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1725000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1671000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	469000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	379000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1295000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	944000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	565000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	565000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	424000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3793000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	948000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2845000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2867000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2867000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2816000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2765000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	51000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	102000	USD
CY2021Q4	aqst	Royalty Receivable RoyaltyReceivable	6000000	USD
CY2020Q4	aqst	Royalty Receivable RoyaltyReceivable	7000000	USD
CY2021Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	903000	USD
CY2020Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	836000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6903000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7836000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	51000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	51000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	51000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5965000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6330000	USD
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	349000	USD
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	316000	USD
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	2224000	USD
CY2020Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1722000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	198000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	201000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8736000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8569000	USD
CY2019Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2000000	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2019Q3	aqst	Net Proceeds From Issuance Of Initial Notes Warrants And First Offer Rights NetProceedsFromIssuanceOfInitialNotesWarrantsAndFirstOfferRights	66082000	USD
CY2021	aqst	Premiums Paid Early Retirement Of Debt PremiumsPaidEarlyRetirementOfDebt	2250000	USD
CY2020Q4	aqst	Premiums Paid Early Retirement Of Debt PremiumsPaidEarlyRetirementOfDebt	2250000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	18025000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	21888000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	11587000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13822000	USD
CY2020Q4	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2909000	USD
CY2020Q4	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	48974000	USD
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	159000	USD
CY2021	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	12253000	USD
CY2021Q4	aqst	Liabilities Sale Of Future Royalties Current LiabilitiesSaleOfFutureRoyaltiesCurrent	1225000	USD
CY2021Q4	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	60284000	USD
CY2021Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	1712000	USD
CY2020Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	1525000	USD
CY2021	aqst	Asset Retirement Obligations Depreciation Expense AssetRetirementObligationsDepreciationExpense	23000	USD
CY2020	aqst	Asset Retirement Obligations Depreciation Expense AssetRetirementObligationsDepreciationExpense	24000	USD
CY2019Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	1360000	USD
CY2020	us-gaap	Asset Retirement Obligation Liabilities Incurred AssetRetirementObligationLiabilitiesIncurred	0	USD
CY2020	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	165000	USD
CY2020Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	1525000	USD
CY2021	us-gaap	Asset Retirement Obligation Liabilities Incurred AssetRetirementObligationLiabilitiesIncurred	0	USD
CY2021	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	187000	USD
CY2021Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	1712000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-70539000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-55783000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38077660	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38077660	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33651127	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33651127	shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.85
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.85
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.66
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.66
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1100000	shares
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6819000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6581000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6819000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6581000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2231000	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.42
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y11M8D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	689000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1168000	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.32
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	140000	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.36
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3259000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.14
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y5M1D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2978000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1212000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.73
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	264000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	7.52
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	61000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.58
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4146000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.28
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M17D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1423000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4026000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.36
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y10M6D
CY2021Q4	aqst	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Or Expected To Vest Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOrExpectedToVestAggregateIntrinsicValue	1377000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1855000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	10.44
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y11M23D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	365000	USD
CY2021Q4	us-gaap	Share Price SharePrice	3.89
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M17D
CY2020Q4	aqst	Deferred Tax Assets Accounts Receivable DeferredTaxAssetsAccountsReceivable	112000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	100000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	4000	USD
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	706000	USD
CY2020	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	673000	USD
CY2021Q4	aqst	Deferred Tax Assets Accounts Receivable DeferredTaxAssetsAccountsReceivable	149000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	309000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	353000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	28722000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22569000	USD
CY2021Q4	aqst	Tax Cuts And Jobs Act Of2017 Deferred Tax Assets Interest Limitation TaxCutsAndJobsActOf2017DeferredTaxAssetsInterestLimitation	9022000	USD
CY2020Q4	aqst	Tax Cuts And Jobs Act Of2017 Deferred Tax Assets Interest Limitation TaxCutsAndJobsActOf2017DeferredTaxAssetsInterestLimitation	7235000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5003000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4051000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2122000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1229000	USD
CY2021Q4	aqst	Deferred Tax Assets Sale Of Future Revenue DeferredTaxAssetsSaleOfFutureRevenue	16595000	USD
CY2020Q4	aqst	Deferred Tax Assets Sale Of Future Revenue DeferredTaxAssetsSaleOfFutureRevenue	14444000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2566000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2380000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	5490000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	5851000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	726000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2547000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	73351000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	58228000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	56769000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	551000	USD
CY2021Q4	aqst	Deferred Tax Liabilities481a Adjustment DeferredTaxLiabilities481aAdjustment	14000	USD
CY2020Q4	aqst	Deferred Tax Liabilities481a Adjustment DeferredTaxLiabilities481aAdjustment	0	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	807000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	908000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	821000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1459000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	72530000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	56769000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	72530000	USD
CY2021Q4	aqst	Number Of Uncertain Tax Positions NumberOfUncertainTaxPositions	0	taxPosition
CY2020Q4	aqst	Number Of Uncertain Tax Positions NumberOfUncertainTaxPositions	0	taxPosition
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0528
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0681
CY2021	aqst	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	-0.0015
CY2020	aqst	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	-0.0012
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0012
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0235
CY2021	aqst	Effective Income Tax Rate Reconciliation Tax Credit Return To Provision Percent EffectiveIncomeTaxRateReconciliationTaxCreditReturnToProvisionPercent	-0.0063
CY2020	aqst	Effective Income Tax Rate Reconciliation Tax Credit Return To Provision Percent EffectiveIncomeTaxRateReconciliationTaxCreditReturnToProvisionPercent	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2237
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3004
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0337
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0012
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2016Q3	aqst	Number Of States In The Antitrust Litigation NumberOfStatesInTheAntitrustLitigation	41	vestingPeriod

Files In Submission

Name	View Source	Status
0001628280-22-005393-index-headers.html	Edgar Link	pending
0001628280-22-005393-index.html	Edgar Link	pending
0001628280-22-005393.txt	Edgar Link	pending
0001628280-22-005393-xbrl.zip	Edgar Link	pending
aqst-12312021xexhibit311.htm	Edgar Link	pending
aqst-12312021xexhibit312.htm	Edgar Link	pending
aqst-12312021xexhibit321.htm	Edgar Link	pending
aqst-12312021xexhibit322.htm	Edgar Link	pending
aqst-20211231.htm	Edgar Link	pending
aqst-20211231.xsd	Edgar Link	pending
aqst-20211231_cal.xml	Edgar Link	unprocessable
aqst-20211231_def.xml	Edgar Link	unprocessable
aqst-20211231_g1.gif	Edgar Link	pending
aqst-20211231_g2.jpg	Edgar Link	pending
aqst-20211231_htm.xml	Edgar Link	completed
aqst-20211231_lab.xml	Edgar Link	unprocessable
aqst-20211231_pre.xml	Edgar Link	unprocessable
ex231kpmgconsent.htm	Edgar Link	pending
executedamendmenttokenda.htm	Edgar Link	pending
executedamendmenttokenda001.jpg	Edgar Link	pending
executedamendmenttokenda002.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
firstamendmenttoamsexecu.htm	Edgar Link	pending
firstamendmenttoamsexecu001.jpg	Edgar Link	pending
firstamendmenttoamsexecu002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AQST
Aquestive Therapeutics, Inc. Stock $aqst

2021 Q4 Form 10-K Financial Statement

#000162828022005393 Filed on March 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST Aquestive Therapeutics, Inc. Stock $aqst

2021 Q4 Form 10-K Financial Statement

#000162828022005393 Filed on March 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST
Aquestive Therapeutics, Inc. Stock $aqst